The pharma stock is up around 17% this year.

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?

The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...

H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.

Vertex ‌Pharmaceuticals will buy ​Crinetics ​Pharmaceuticals for a total ⁠equity ​value of ​about $10 billion, the companies said ​on ​Monday.

The acquisition is expected to close in the third quarter of 2026.

Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...

Vertex Pharmaceuticals to acquire Crinetics (CRNX) for $10 billion in all-cash deal at $85 per share, gaining key ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

An announcement from Crinetics Pharmaceuticals ( (CRNX)) is now available. On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals signed a definitive merger agreement under which Vertex ...